Survivin inhibits apoptosis and promotes mitosis. We determined whether nuclear or cytoplasmic localisation of survivin predicts survival of 48 patients with resected non-small-cell lung cancer (NSCLC). Patients with nuclear staining of survivin had significantly worse survival (relative risk: 3.9, P = 0.02). Therefore, survivin may be a biomarker for NSCLC.
|Number of pages||4|
|Journal||British Journal of Cancer|
|State||Published - Aug 2 2004|
- Lung cancer nucleus
- Tissue array